1 week ago
Amylyx (AMLX) Stock Surges Past 52-Week High on Successful Avexitide Phase 3 Results
Amylyx (AMLX) stock soared 21% after avexitide succeeded in Phase 3 trial. Mizuho raises target to $30 with 2027 launch expected. Full trial results inside.
The post Amylyx (AMLX) Stock Surges Past 52-Week High on Successful Avexitide Phase 3 Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 10 hours ago
The Trade Desk, Inc. (TTD) Stock: New Zuma Platform Brings Smarter AI, Simpler M...
- 10 hours ago
Laser Photonics Corporation (LASE) Stock: SOCOM Engagement Puts Counter-Drone Sy...
- 13 hours ago
Amazon (AMZN) Stock: Expands Nvidia Partnership as AI Demand Grows
- 13 hours ago
Marvell Technology (MRVL) Q2 Earnings Preview: Should Investors Buy Before Thurs...
- 13 hours ago
Nvidia (NVDA), Salesforce (CRM), CrowdStrike (CRWD), and Okta (OKTA) Soar as AI...